Sequence Specific and Organism Specific Antimicrobials and Related Materials and Methods

a specific and organism-specific technology, applied in the field of sequence specific and organism-specific antimicrobials and related materials and methods, can solve the problems of antibiotic approval through the u.s. fda, antibiotic development continues to stagnate, and antibiotics represent a relatively poor return on research and development investment,

Inactive Publication Date: 2018-01-04
UNIV OF COLORADO THE REGENTS OF
View PDF6 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present invention describes methods that can identify specific genes associated with bacteria's ability to resist drugs called AMYLANA® (an example drug). These techniques help researchers better study how they are doing their job by creating small molecules that bind specifically against these genes or alter them from those already known on other organisms. This allows scientists to develop new ways to fight off harmful microorganism populations without causing any negative side-effects like adding more chemical agents into our food supply systems.

Problems solved by technology

The technical problem addressed in this patents relates to developing effective treatments that target both Gram negative and gram positive microorganism populations without causing resistance issues like those associated with traditional chemotherapy methods used today.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Sequence Specific and Organism Specific Antimicrobials and Related Materials and Methods
  • Sequence Specific and Organism Specific Antimicrobials and Related Materials and Methods
  • Sequence Specific and Organism Specific Antimicrobials and Related Materials and Methods

Examples

Experimental program
Comparison scheme
Effect test

examples

[0113]The materials, methods, and embodiments described herein are further defined in the following Examples. Certain embodiments of the present invention are defined in the Examples herein. It should be understood that these Examples, while indicating certain embodiments of the invention, are given by way of illustration only. From the discussion herein and these Examples, one skilled in the art can ascertain the essential characteristics of this invention and without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions.

example i

and Methods

[0114]Bacterial Strains and Cell Culture Conditions.

[0115]pAKgfp1 plasmid was obtained from Addgene for TEM-1 β-lactamase resistance gene, bla (43). The plasmid was cloned into chemically competent Zymo DH5a E. coli (Expressys). Untransformed Zymo DH5a was used as a control strain for β-lactamase activity assays. Liquid cultures were grown in 2% LB, incubated at 37° C. and shaken at 225 rpm. Solid cultures were grown on 2% LB broth, 1.5% agar at 37° C. Ampicillin sodium salt (Sigma Aldrich) was used for selection at a concentration of 300 μg / mL for MIC and CFU analysis. Optical density measurements were taken using a Tecan GENios at 562 nm with a bandwidth of 35 nm. All bacterial freezer stocks were stored in 40% glycerol at −80° C.

[0116]MG1655 E. coli cultures were started from individual colonies from 2% LB and 1.5% agar into M9 media. They were diluted 1:10,000 from overnight culture into fresh M9 with respective treatment and grown at 37° C. with 225 rpm shaking. Clini

example ii

the Ribosomal Binding Site and Translation Start Site Reverts β-Lactamase Resistance

[0137]Protein functional sites on mRNA have been shown to be effective antisense sites for blocking ribosomal binding and migration. These include the ribosomal binding site (RBS) and translation start site (TSS), which are located in the 5′ untranslated region (UTR). The antisense oligomers disclosed and described herein are predicted to sterically hinder the ribosome. In order to prevent the production of truncated, but potentially active, β-lactamase enzyme, the 5′ UTR of bla mRNA was targeted (27).

[0138]Three different antisense oligomers were designed against target sites proximal to the 5′ UTR of bla mRNA: α-RBS; α-TSS; and α-YUNR (FIGS. 1B and 6) (28). Antisense oligomers were designed with the target sequence in the middle of the oligomer, with 3-5 nucleotides flanking the overlapping region (27). To prevent translation of β-lactamase, two short 12-mer antisense oligomers—α-RBS (C-ATAACTTTTTCC-N

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Lengthaaaaaaaaaa
Electrical resistanceaaaaaaaaaa
Nucleic acid sequenceaaaaaaaaaa
Login to view more

Abstract

Described herein are RNA-based antisense therapeutics to target antibiotic resistant bacteria. The antisense therapeutics disclosed herein can be useful in re-sensitizing drug-resistant bacteria to antibiotics, as well as developing antibiotics that have bactericidal or bacteriostatic effects on the drug-resistant bacteria or are capable of preventing emergence of antibiotic resistance. Also described herein are methods for re-sensitizing a subject to one or more antibiotics in need thereof, methods for identifying target genes involved in adaptive antibiotic resistance in bacteria, and methods for developing antibacterial antisense therapeutics.

Description

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Owner UNIV OF COLORADO THE REGENTS OF
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products